Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referred to as Enlivex Ltd. in metadata) covers the month of October 2017. The report addresses the company's regulatory status regarding its listing on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance.
Material Changes
- Share Capital Restructuring: The Company effected a 5 to 1 reverse split of its share capital on September 25, 2017.
- Listing Compliance: Following the reverse split, the closing bid price of the Company's ordinary shares remained at $1.00 per share or greater for 10 consecutive business days.
- Regulatory Status: On October 10, 2017, NASDAQ confirmed the Company regained compliance with Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond the previously noted risk of delisting due to low share price. The matter regarding the minimum bid price requirement is now closed.
Investor Verification Checklist
- Verify the effective date and ratio of the 5 to 1 reverse stock split.
- Confirm the current trading price of the ordinary shares to ensure continued compliance with the $1.00 minimum bid price.
- Review subsequent filings for any new compliance notices or financial updates, as this filing contains no financial data.